Bioventus Inc. is an undervalued medical device stock to watch, with Cantor Fitzgerald initiating coverage with an Overweight rating and $12 price target. The company reported a 4.3% decline in revenue for Q1 2025, but also saw a 5.0% growth in organic revenue, driven by positive growth across its businesses.

Global revenue in Paint Treatments rose 3.9%, driven by demand for Durolane, a single-injection hyaluronic acid therapy for knee osteoarthritis. Surgical Solutions also saw a 7.0% growth in revenue, attributed to strong capital equipment purchases in the US. Bioventus operates through various business segments, focusing on orthobiologic products.

While Bioventus shows potential, certain AI stocks may offer greater upside. Consider exploring the best short-term AI stock for investment opportunities. Check out other articles for insights on stocks that could double in three years and hidden AI stocks to buy now. This article is published at Insider Monkey.

Read more at Yahoo Finance: Cantor Fitzgerald Initiates Coverage of Bioventus (BVS) with an Overweight Rating